A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine Once Daily Compared to Atazanavir and Ritonavir Plus Tenofovir/Emtricitabine Once Daily in HIV-1 Infected Antiretroviral Therapy Naïve Women

CompletadoFase 3ClinicalTrials.gov

ID: NCT01910402Tipo: INTERVENTIONALInicio: 22 de ago de 2013Fin estimado: 18 de ago de 2022

Enfermedades Infecciosas Alergia e Inmunología

Traducción no disponible, mostrando original

Resumen

This study is designed to demonstrate the non-inferior antiviral activity of DTG/ABC/3TC fixed dose combination (FDC) once daily (OD) compared to atazanavir plus ritonavir (ATV+RTV) and tenofovir disoproxil fumarate/emtricitabine fixed dose combination (TDF/FTC FDC) OD in HIV-1 infected, ART-naïve women over 48 weeks. This study will also characterize the safety and tolerability of DTG/ABC/3TC FDC compared to ATV+RTV+TDF/FTC FDC. Sufficient number of subjects will be screened in order to ensure a total of approximately 474 subjects will be randomized (237 in each study arm)

Elegibilidad

Edad mínima: 18 YearsSexo: FEMALE

Criterios de inclusión

HIV-1 infected females (gender at birth) \>=18 years of age
Women capable of becoming pregnant must use appropriate contraception during the study (as defined by the protocol)
HIV-1 infection as documented by Screening plasma HIV-1 RNA \>=500 c/mL.
Documentation that the subject is negative for the HLA-B\*5701 allele.
Antiretroviral-naïve (\<=10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection).
Signed and dated written informed consent is obtained from the subject or the subject's legal representative prior to screening.

Criterios de exclusión

Women who are pregnant or breastfeeding
Women who plan to become pregnant during the first 48 weeks of the study
Any subject who has had a medical intervention for gender reassignment
Any evidence of an active Centers for Disease Control and Prevention (CDC) Category C disease
Subjects with any degree of hepatic impairment
Subjects positive for hepatitis B at Screening, or anticipated need for HCV therapy during the study
History or presence of allergy to the study drugs or their components or drugs of their class
Ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia
poses a significant suicidality risk
History of osteoporosis with fracture or requiring pharmacologic therapy
Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening
Treatment with any of the following agents within 28 days of Screening: radiation therapy; cytotoxic chemotherapeutic agents; any immunomodulators that alter immune responses;
Treatment with any agent, with documented activity against HIV-1 in vitro within 28 days of first dose of investigational product (IP)
Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of IP
Any evidence of primary viral resistance based on the presence of any major resistance-associated mutation in the Screening result or, if known, any historical resistance test result
Any verified Grade 4 laboratory abnormality, with the exception of Grade 4 lipid abnormalities (total cholesterol, triglycerides, High Density Lipoprotein (HDL) cholesterol, Low Density Lipoprotein (LDL) cholesterol)
Any acute laboratory abnormality at Screening, which, in the opinion of the Investigator, would preclude the subject's participation in the study of an investigational compound
Alanine aminotransferase (ALT) ≥5 times the upper limit of normal (ULN), or ALT ≥ 3xULN and bilirubin ≥ 1.5xULN (with \>35% direct bilirubin)
Subject has CrCL of \<50 mL/min via Cockroft-Gault method
Corrected QT interval (QTc (Bazett)) ≥450msec or QTc (Bazett) ≥480msec for subjects with bundle branch block.

Intervenciones

drug

Dolutegravir/abacavir/lamivudine FDC

Dolutegravir/abacavir/lamivudine FDC tablets, 50 mg/600 mg/300 mg

drug

Atazanavir

Atazanavir capsule 300 mg

drug

Ritonavir

Ritonavir tablet 100 mg

drug

Tenofovir/emtricitabine FDC

Tenofovir/emtricitabine FDC tablet 300 mg/200 mg of FTC

Ubicaciones

GSK Investigational Site

Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

GSK Investigational Site

Ciudad de Buenos Aires, Buenos Aires, Argentina

GSK Investigational Site

Buenos Aires, Argentina

Patrocinadores

PrincipalViiV Healthcare

ColaboradorGlaxoSmithKline

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Phase IIIb, Randomized, Open-label Study of the Safety ... | EligiMed